A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice

Qiuhong Miao; Wilson Nguyen; Jie Zhu; Guangqing Liu; Monique M. van Oers; Bing Tang; Kexin Yan; Thibaut Larcher; Andreas Suhrbier; Gorben P. Pijlman

doi:10.1016/j.vaccine.2024.07.037

A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice

Qiuhong Miao^*, Wilson Nguyen, Jie Zhu, Guangqing Liu, Monique M. van Oers, Bing Tang, Kexin Yan, Thibaut Larcher, Andreas Suhrbier, Gorben P. Pijlman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Getah virus (GETV) is an emerging mosquito-borne virus with economic impact on the livestock industry in East Asia. In this study, we successfully produced GETV virus-like particles (VLPs) in insect cells using the baculovirus expression vector system. We show that the GETV envelope glycoproteins were successfully expressed at the surface of the insect cell and were glycosylated. VLPs were isolated from the culture fluid as enveloped particles of 60–80 nm in diameter. Two 1 µg vaccinations with this GETV VLP vaccine, without adjuvant, generated neutralizing antibody responses and protected wild-type C57/BL6 mice against GETV viremia and arthritic disease. The GETV VLP vaccine may find application as a horse and/or pig vaccine in the future.

Original language	English
Article number	126136
Pages (from-to)	126136
Journal	Vaccine
Volume	42
Issue number	25
Early online date	2024
DOIs	https://doi.org/10.1016/j.vaccine.2024.07.037
Publication status	Published - 2024

Keywords

Baculovirus
Getah virus
Mouse model
Vaccine
Virus-like-particle

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2024.07.037Licence: CC BY

https://edepot.wur.nl/670768Licence: CC BY

Cite this

@article{97fb52f94ab8469da63e2bc912526441,

title = "A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice",

abstract = "Getah virus (GETV) is an emerging mosquito-borne virus with economic impact on the livestock industry in East Asia. In this study, we successfully produced GETV virus-like particles (VLPs) in insect cells using the baculovirus expression vector system. We show that the GETV envelope glycoproteins were successfully expressed at the surface of the insect cell and were glycosylated. VLPs were isolated from the culture fluid as enveloped particles of 60–80 nm in diameter. Two 1 µg vaccinations with this GETV VLP vaccine, without adjuvant, generated neutralizing antibody responses and protected wild-type C57/BL6 mice against GETV viremia and arthritic disease. The GETV VLP vaccine may find application as a horse and/or pig vaccine in the future.",

keywords = "Baculovirus, Getah virus, Mouse model, Vaccine, Virus-like-particle",

author = "Qiuhong Miao and Wilson Nguyen and Jie Zhu and Guangqing Liu and {van Oers}, {Monique M.} and Bing Tang and Kexin Yan and Thibaut Larcher and Andreas Suhrbier and Pijlman, {Gorben P.}",

year = "2024",

doi = "10.1016/j.vaccine.2024.07.037",

language = "English",

volume = "42",

pages = "126136",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "25",

}

TY - JOUR

T1 - A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice

AU - Miao, Qiuhong

AU - Nguyen, Wilson

AU - Zhu, Jie

AU - Liu, Guangqing

AU - van Oers, Monique M.

AU - Tang, Bing

AU - Yan, Kexin

AU - Larcher, Thibaut

AU - Suhrbier, Andreas

AU - Pijlman, Gorben P.

PY - 2024

Y1 - 2024

N2 - Getah virus (GETV) is an emerging mosquito-borne virus with economic impact on the livestock industry in East Asia. In this study, we successfully produced GETV virus-like particles (VLPs) in insect cells using the baculovirus expression vector system. We show that the GETV envelope glycoproteins were successfully expressed at the surface of the insect cell and were glycosylated. VLPs were isolated from the culture fluid as enveloped particles of 60–80 nm in diameter. Two 1 µg vaccinations with this GETV VLP vaccine, without adjuvant, generated neutralizing antibody responses and protected wild-type C57/BL6 mice against GETV viremia and arthritic disease. The GETV VLP vaccine may find application as a horse and/or pig vaccine in the future.

AB - Getah virus (GETV) is an emerging mosquito-borne virus with economic impact on the livestock industry in East Asia. In this study, we successfully produced GETV virus-like particles (VLPs) in insect cells using the baculovirus expression vector system. We show that the GETV envelope glycoproteins were successfully expressed at the surface of the insect cell and were glycosylated. VLPs were isolated from the culture fluid as enveloped particles of 60–80 nm in diameter. Two 1 µg vaccinations with this GETV VLP vaccine, without adjuvant, generated neutralizing antibody responses and protected wild-type C57/BL6 mice against GETV viremia and arthritic disease. The GETV VLP vaccine may find application as a horse and/or pig vaccine in the future.

KW - Baculovirus

KW - Getah virus

KW - Mouse model

KW - Vaccine

KW - Virus-like-particle

U2 - 10.1016/j.vaccine.2024.07.037

DO - 10.1016/j.vaccine.2024.07.037

M3 - Article

AN - SCOPUS:85198381543

SN - 0264-410X

VL - 42

SP - 126136

JO - Vaccine

JF - Vaccine

IS - 25

M1 - 126136

ER -

A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this